Sotio
Sotio a.s. [1] is a biotechnology company belonging to the PPF Group owned by Petr Kellner. Since March 2014, the head of the company is Ladislav Bartoníček,[2] the former head of Česká pojišťovna (Czech Insurance Company). The company focuses on research and development of medicines for cancer and autoimmune diseases.[3] Besides European countries, it also operate in the USA, Russia and China.[1] In 2014, the Sotio company opened a laboratory complex in China where it produce drugs for people suffering from oncological diseases.[4] Similar laboratories opened in Prague in 2011 already.
The company became well known for developing drugs for prostate cancer, ovarian cancer [5] and lung cancer.[3][6]
In August 2018, Sotio acquired Cytune Pharma.[7] and announced to continue development of both the company's lead program SO-C101 (RLI-15) which is a human fusion protein of IL-15 and the high-affinity binding domain of IL-15Ra. It is a novel immunotherapeutic approach with potential applications in a variety of oncology indications. The first clinical trial for the program is expected to be launched in 2019.[8][9]
References
- 1 2 "The company - About us - Sotio a.s." sotio.com.
- ↑ "Kellnerovo biotechnologické Sotio povede exšéf České pojišťovny Bartoníček". Hospodářské noviny.
- 1 2 "Kellnerova firma Sotio zahájila testy léku na rakovinu plic". E15.cz.
- ↑ "Firma Sotio otevřela v Číně laboratoř, má pomoci proti rakovině". mednes.cz.
- ↑ "Kellnerova firma začala test léku na rakovinu vaječníků". Aktuálně.cz - Víte co se právě děje.
- ↑ Zuzana Kubátová (6 January 2015). "Kellnerova firma začíná testovat už třetí lék, tentokrát na nádory plic". iDNES.cz.
- ↑ Letter, The Pharma. "SOTIO completes acquisition of Cytune Pharma". www.thepharmaletter.com. Retrieved 2018-09-18.
- ↑ "SOTIO, biotech major acquires Cytune Pharma". ehealth.eletsonline.com. Retrieved 2018-09-18.
- ↑ "PPF Group & Sotio complete acquisition of Cytune". EPM Magazine. 2018-08-31. Retrieved 2018-09-18.